NCT02241499View on ClinicalTrials.gov

Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Adenocarcinoma of the Esophagus or Esophagogastric Junction
Interventions
RADIATION

Radiation therapy

Radiotherapy at a dose of 4 Gy will be given to a total dose of 20 Gy, treatment duration 5 days.

DRUG

Oxaliplatin and fluorouracil.

Oxaliplatin at a dose of 85 mg/m2 and will be given on day 1, infusion (44 hours) of fluorouracil will be given for 4 cycles, cycle length 14 days.

Trial Locations (1)

221 85

Lund University Hospital, Department of Oncology, Lund

All Listed Sponsors
lead

Lund University Hospital

OTHER

NCT02241499 - Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol. | Biotech Hunter | Biotech Hunter